Naltrexone/Bupropion (Mysimba) to Optimize Weight Outcomes After Obesity Surgery
Status:
Withdrawn
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Limited/poor weight loss and weight regain are concerns following bariatric surgery, and
weight regain may increase the risk for relapse of comorbidities related to obesity.
Medications for weight reduction may assist further weight loss, and support weight
maintenance, with positive effects on comorbidities. This pilot study will examine the effect
of naltrexone/bupropion and lifestyle advice versus lifestyle advice alone for 7 months in
patients with a suboptimal weight trajectory (either little weight loss or weight regain) 2
years or later following bariatric surgery.